Clinical Trial

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Protocol Amendment History 2 changes
notable Trial sites reduced: 276 -> 254 locations 2026-07-19
notable Trial sites expanded: 249 -> 272 locations 2026-04-15
Trial Details
NCT Number NCT07284849
Lead Sponsor Incyte Corporation
Conditions CRC (Colorectal Cancer)
Enrollment 700 participants
Start Date 2026-03-05
Primary Completion 2028-12-29 (estimated)
Study Completion 2029-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-06